A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Open to people ages 12-99

• A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:
• ≥ 0.5 F-VASI on the face
• ≥ 3.0 T-VASI (body areas not including the face)
• Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
• Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.

• No pigmented hair within any of the vitiligo areas on the face.
• Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders.
• Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
• Previous adverse reaction to NB-UVB phototherapy that caused discontinuation of therapy.
• Lack of response (little or no repigmentation) to prior NB-UVB phototherapy.
• History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction).
• Any other skin disease that, in the opinion of the investigator, would interfere with the study cream application or study assessments.
• Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline.
• Any serious illness or medical, physical, or psychiatric condition(s) that pose a significant risk to the participant; or interfere with interpretation of study data.
• Recent use of topical or systemic medications (including biologics or JAK inhibitors), or laser or phototherapy to treat vitiligo. Note: Recent may be defined differently for different treatments.
• Specific protocol-defined chemistry, hematology, and serological lab values.
• Those who are pregnant, lactating or considering pregnancy during the period of study participation.